FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

<b>STATEMENT</b>	<b>OF CHANGES</b>	IN BENEFICIAL	<b>OWNERSHIP</b>

OMB APPRO	VAL				
OMB Number:	3235-0287				
Estimated average burde	en				
hours per response:	0.5				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Dallas Jayson Donald Alexander						2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Ultragenyx Pharmaceutical Inc.</u> [ RARE ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner  Officer (give title Other (specify below)						
(Last) (First) (Middle) C/O ULTRAGENYX PHARMACEUTICAL INC. 60 LEVERONI COURT				06	3. Date of Earliest Transaction (Month/Day/Year) 06/01/2016									See Remarks						
(Street) NOVATO			94949 (Zip)		_   4.	4. If Amendment, Date of Original Filed (Month/Day/Year)				Lin	Individual or Joint/Group Filing (Check Applicable ne)  X Form filed by One Reporting Person Form filed by More than One Reporting Person									
(9)	(-	-	le I - Non	-Deriv	vativ	e Se	curities	S Ac	auired.	Disi	osed o	f. or Be	neficial	lv Ov	vned					
1. Title of Security (Instr. 3)  2. Transa Date (Month/D:			saction	2A. Deemed Execution Date,		3. 4. Securities Acquired (A) of Transaction Code (Instr. 5)		ed (A) or	or 5. Amou 4 and Securitie Benefici Owned F		s ally following	Form (D) o	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership						
						Code	v	Amount	nount (A) or (D)		l Tra	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)				
Common Stock 06/01/			1/201	/2016		A		3,400 <sup>(1)</sup> A		\$0.0	13,400 <sup>(2)</sup>			D						
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Yea	Date,	4. Transaction Code (Instr 8)				6. Date Exercisa Expiration Date (Month/Day/Yea			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	Owne Form: Direct or Ind (I) (Ins	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisabl		xpiration vate	Title	Amount or Number of Shares							
Employee Stock Option (Right to Buy)	\$70.57	06/01/2016			A		20,200		(3)	0	6/01/2026	Common Stock	20,200	\$0.	.00	20,200	0	D		

## **Explanation of Responses:**

- 1. Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date.
- 2. Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
- 3. On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.

## Remarks:

SVP and Chief Commercial Officer

/s/ Shalini Sharp by power of attorney for Jayson Dallas

06/03/2016

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.